Thought Leader: Richard Malcolm, CEO, Acurian
In this episode, Dr. Malcolm discusses how the role of the CRO is transitioning from commodity service supplier to strategic partner, and the unintended negative consequences this could have on what is already the most expensive part of clinical trials: patient enrollment.
Play Podcast
In this episode, Dr. Malcolm discusses how the role of the CRO is transitioning from commodity service supplier to strategic partner, and the unintended negative consequences this could have on what is already the most expensive part of clinical trials: patient enrollment.
Play Podcast
For more information on how you can be featured in a podcast, contact Dan Limbach at dlimbach@pharmavoice.com or call him at (847) 594-0157.
